MedWatch

Novo Nordisk silent about the loss of massive contract

The Danish pharmaceutical company will wait until its quarterly statement to assess the future and the impact of incidents such as the one that had the company’s share dipping significantly today.

Foto: Novo Nordisk/PR

A contract believed to account for a significant share of Novo Nordisks volumes in the US has slipped from the grip of the Danish pharmaceutical group and into the hands of fierce rival, Eli Lilly.

The contract in question is with US company Express Scripts, the largest pharmacy benefit management organization in the United States. But Novo Nordisk is reluctant to comment on the lost contract, which has caused its share price to drop by 3 %.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier